Bod Australia Limited entered into an exclusive manufacturing and commercialisation agreement with iX Biopharma Ltd. Under the Agreement, Bod Australia will supply iX Biopharma with a range of medicinal cannabis extracts including oils and raw materials. These extracts will be utilised by iX Biopharma to create a unique natural medicine product delivered on iX Biopharma's proprietary WaferiXTM technology for use in the Company's Phase I Clinical trials. Market leading WaferiXTM technology consists of a small wafer, formulated using a proprietary freeze-drying process. The wafer, intended to be placed under the consumer's tongue, dissolves within one minute. It releases contained active compounds for rapid absorption. The wafer administration is tolerable with no after-taste, leaving behind no residue or grittiness under the tongue preventing the urge for recipients to swallow. The wafer style drug delivery method will be manufactured through iX Biopharma's wholly owned Australian subsidiary, iX Syrinx Pty Ltd. The product will be manufactured in state-of-the-art, Therapeutic Goods Administration (TGA) and Good Manufacturing Practice (GMP) approved pharmaceutical manufacturing in Melbourne, Victoria. This is expected to fast track the commencement of trials and defraying any import risks.